company background image
474

Aceso Life Science Group SEHK:474 Stock Report

Last Price

HK$0.14

Market Cap

HK$1.0b

7D

-1.4%

1Y

-38.2%

Updated

23 Jun, 2022

Data

Company Financials
474 fundamental analysis
Snowflake Score
Valuation1/6
Future Growth0/6
Past Performance0/6
Financial Health4/6
Dividends0/6

474 Stock Overview

Aceso Life Science Group Limited, an investment holding company, engages in money lending, securities investment, asset management, other financial service, property leasing and development, rental and trading of construction machinery, and bioscience businesses.

Aceso Life Science Group Competitors

 

 

 

 

 

 

 

 

 

 

 

 

Price History & Performance

Summary of all time highs, changes and price drops for Aceso Life Science Group
Historical stock prices
Current Share PriceHK$0.14
52 Week HighHK$0.23
52 Week LowHK$0.042
Beta-0.040
1 Month Change-8.11%
3 Month Change97.10%
1 Year Change-38.18%
3 Year Change-40.87%
5 Year Change-51.92%
Change since IPO-96.64%

Recent News & Updates

Shareholder Returns

474HK Consumer FinanceHK Market
7D-1.4%2.0%1.2%
1Y-38.2%-15.6%-23.3%

Return vs Industry: 474 underperformed the Hong Kong Consumer Finance industry which returned -17.3% over the past year.

Return vs Market: 474 underperformed the Hong Kong Market which returned -23.8% over the past year.

Price Volatility

Is 474's price volatile compared to industry and market?
474 volatility
474 Average Weekly Movement32.2%
Consumer Finance Industry Average Movement8.2%
Market Average Movement7.0%
10% most volatile stocks in HK Market13.7%
10% least volatile stocks in HK Market3.3%

Stable Share Price: 474 is more volatile than 90% of Hong Kong stocks over the past 3 months, typically moving +/- 32% a week.

Volatility Over Time: 474's weekly volatility has increased from 21% to 32% over the past year.

About the Company

FoundedEmployeesCEOWebsite
2005167n/ahttps://www.acesogrouphk.com

Aceso Life Science Group Limited, an investment holding company, engages in money lending, securities investment, asset management, other financial service, property leasing and development, rental and trading of construction machinery, and bioscience businesses. The company provides property mortgage and personal loans to individuals and corporates; unsecured loans to individual high-end customers; and commodities, futures, and securities brokerage services, as well as rents and trades in construction machinery, including crawler cranes, other mobile cranes, aerial platforms, and foundation equipment; and spare parts. It also offers repair and maintenance services for construction machinery; and transportation services, such as local container delivery, construction site delivery, and heavy machinery transport.

Aceso Life Science Group Fundamentals Summary

How do Aceso Life Science Group's earnings and revenue compare to its market cap?
474 fundamental statistics
Market CapHK$1.00b
Earnings (TTM)-HK$25.00m
Revenue (TTM)HK$73.00m

13.8x

P/S Ratio

-40.2x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
474 income statement (TTM)
RevenueHK$73.00m
Cost of RevenueHK$135.00m
Gross Profit-HK$62.00m
Other Expenses-HK$37.00m
Earnings-HK$25.00m

Last Reported Earnings

Sep 30, 2021

Next Earnings Date

Jun 29, 2022

Earnings per share (EPS)-0.0034
Gross Margin-84.93%
Net Profit Margin-34.25%
Debt/Equity Ratio101.9%

How did 474 perform over the long term?

See historical performance and comparison
We’ve recently updated our valuation analysis.

Valuation

Is 474 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

1/6

Valuation Score 1/6

  • Price-To-Book vs Peers

  • Price-To-Book vs Industry

  • Price-To-Book vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • PEG Ratio

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 474?

Other financial metrics that can be useful for relative valuation.

474 key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenuen/a
Enterprise Value/EBITDAn/a
PEG Ration/a

Price to Book Ratio vs Peers

How does 474's PB Ratio compare to its peers?

474 PB Ratio vs Peers
The above table shows the PB ratio for 474 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPBEstimated GrowthMarket Cap
Peer Average0.6x

Price-To-Book vs Peers: 474 is good value based on its Price-To-Book Ratio (0.5x) compared to the peer average (0.6x).


Price to Earnings Ratio vs Industry

How does 474's PE Ratio compare vs other companies in the Hong Kong Consumer Finance Industry?

Price-To-Book vs Industry: 474 is expensive based on its Price-To-Book Ratio (0.5x) compared to the Hong Kong Consumer Finance industry average (0.4x)


Price to Book Ratio vs Fair Ratio

What is 474's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

474 PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio0.5x
Fair PB Ration/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate 474's Price-To-Book Fair Ratio for valuation analysis.


Share Price vs Fair Value

What is the Fair Price of 474 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate 474's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate 474's fair value for valuation analysis.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate 474's PEG Ratio to determine if it is good value.


Discover undervalued companies

Future Growth

How is Aceso Life Science Group forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

Future Growth Score

0/6

Future Growth Score 0/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


21.4%

Forecasted Diversified Financials industry annual growth in earnings

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Aceso Life Science Group has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Discover growth companies

  • Examine Aceso Life Science Group's financial health to determine how well-positioned it is against times of financial stress by looking at its level of debt over time and how much cash it has left.
  • Aceso Life Science Group competitive advantages and company strategy can generally be found in its financial reports archived here.

Past Performance

How has Aceso Life Science Group performed over the past 5 years?

Past Performance Score

0/6

Past Performance Score 0/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


46.9%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: 474 is currently unprofitable.

Growing Profit Margin: 474 is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: 474 is unprofitable, but has reduced losses over the past 5 years at a rate of 46.9% per year.

Accelerating Growth: Unable to compare 474's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: 474 is unprofitable, making it difficult to compare its past year earnings growth to the Consumer Finance industry (4.2%).


Return on Equity

High ROE: 474 has a negative Return on Equity (-0.66%), as it is currently unprofitable.


Discover strong past performing companies

Financial Health

How is Aceso Life Science Group's financial position?

Financial Health Score

4/6

Financial Health Score 4/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Stable Cash Runway

  • Forecast Cash Runway

Financial Position Analysis

Short Term Liabilities: 474's short term assets (HK$2.7B) exceed its short term liabilities (HK$954.0M).

Long Term Liabilities: 474's short term assets (HK$2.7B) exceed its long term liabilities (HK$2.6B).


Debt to Equity History and Analysis

Debt Level: 474's net debt to equity ratio (59.3%) is considered high.

Reducing Debt: 474's debt to equity ratio has increased from 16.8% to 101.9% over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: Whilst unprofitable 474 has sufficient cash runway for more than 3 years if it maintains its current positive free cash flow level.

Forecast Cash Runway: 474 is unprofitable but has sufficient cash runway for more than 3 years, due to free cash flow being positive and growing by 16.5% per year.


Discover healthy companies

Dividend

What is Aceso Life Science Group current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Future Dividend Coverage

Dividend Yield vs Market

Notable Dividend: Unable to evaluate 474's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate 474's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if 474's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if 474's dividend payments have been increasing.


Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as 474 has not reported any payouts.


Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?

5.6yrs

Average management tenure


CEO

Aceso Life Science Group has no CEO, or we have no data on them.


Leadership Team

Experienced Management: 474's management team is seasoned and experienced (5.6 years average tenure).


Board Members

Experienced Board: 474's board of directors are considered experienced (9.9 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: 474 insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 6.5%.


Top Shareholders

Company Information

Aceso Life Science Group Limited's employee growth, exchange listings and data sources


Key Information

  • Name: Aceso Life Science Group Limited
  • Ticker: 474
  • Exchange: SEHK
  • Founded: 2005
  • Industry: Consumer Finance
  • Sector: Diversified Financials
  • Implied Market Cap: HK$1.004b
  • Shares outstanding: 7.38b
  • Website: https://www.acesogrouphk.com

Number of Employees


Location

  • Aceso Life Science Group Limited
  • Rooms 2501–2509, Shui On Centre
  • 25th Floor
  • Wan Chai
  • Hong Kong

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/06/23 00:00
End of Day Share Price2022/06/23 00:00
Earnings2021/09/30
Annual Earnings2021/03/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.